Innovative Cellular Therapeutics Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$40M
- Investors
-
10
Innovative Cellular Therapeutics General Information
Description
Developer of chimeric antigen receptor T cells products designed to treat blood cancers and solid tumors. The company is developing cellular immunotherapies for the treatment of late-stage solid tumors, such as colorectal cancer and thyroid cancer, enabling patients to recover from cancer disease and live healthy life.
Contact Information
Website
www.ictbio.comCorporate Office
- 50 West Gude Drive
- Suite 60
- Rockville, MD 20850
- United States
Corporate Office
- 50 West Gude Drive
- Suite 60
- Rockville, MD 20850
- United States
Innovative Cellular Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 06-Sep-2021 | $40M | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC (Series B1) | 01-Nov-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 11-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series A) | 08-Oct-2016 | Completed | Clinical Trials - Phase 1 | |||
| 1. Later Stage VC | 08-Feb-2015 | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Innovative Cellular Therapeutics Patents
Innovative Cellular Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020086989-A1 | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy | Inactive | 25-Oct-2018 | ||
| WO-2020047306-A1 | Chimeric antigen receptor cells for treating solid tumor | Inactive | 30-Aug-2018 | ||
| JP-2021510540-A | Amplification of modified cells and their applications | Pending | 11-Jan-2018 | ||
| CA-3088161-A1 | Modified cell expansion and uses thereof | Pending | 11-Jan-2018 | ||
| WO-2019140100-A1 | Modified cell expansion and uses thereof | Inactive | 11-Jan-2018 | C12N15/625 |
Innovative Cellular Therapeutics Signals
Innovative Cellular Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| i-Qu & Co | Venture Capital | Minority | ||
| Hyfinity Investments | Growth/Expansion | Minority | ||
| LH Ventures (China) | PE/Buyout | Minority | ||
| Dunhou Capital | Venture Capital | Minority | ||
| SB China Venture Capital | Venture Capital | Minority |
Innovative Cellular Therapeutics FAQs
-
When was Innovative Cellular Therapeutics founded?
Innovative Cellular Therapeutics was founded in 2009.
-
Where is Innovative Cellular Therapeutics headquartered?
Innovative Cellular Therapeutics is headquartered in Rockville, MD.
-
What is the size of Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics has 14 total employees.
-
What industry is Innovative Cellular Therapeutics in?
Innovative Cellular Therapeutics’s primary industry is Drug Discovery.
-
Is Innovative Cellular Therapeutics a private or public company?
Innovative Cellular Therapeutics is a Private company.
-
What is Innovative Cellular Therapeutics’s current revenue?
The current revenue for Innovative Cellular Therapeutics is .
-
How much funding has Innovative Cellular Therapeutics raised over time?
Innovative Cellular Therapeutics has raised $68.3M.
-
Who are Innovative Cellular Therapeutics’s investors?
i-Qu & Co, Hyfinity Investments, LH Ventures (China), Dunhou Capital, and SB China Venture Capital are 5 of 10 investors who have invested in Innovative Cellular Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process